Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.

<h4>Background</h4>Important support functions, including promotion of tumor growth, angiogenesis, and invasion, have been attributed to the different cell types populating the tumor stroma, i.e., endothelial cells, cancer-associated fibroblasts, pericytes, and infiltrating inflammatory...

Full description

Bibliographic Details
Main Authors: Kristian Pietras, Jessica Pahler, Gabriele Bergers, Douglas Hanahan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-01-01
Series:PLoS Medicine
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18232728/?tool=EBI
_version_ 1818566893028507648
author Kristian Pietras
Jessica Pahler
Gabriele Bergers
Douglas Hanahan
author_facet Kristian Pietras
Jessica Pahler
Gabriele Bergers
Douglas Hanahan
author_sort Kristian Pietras
collection DOAJ
description <h4>Background</h4>Important support functions, including promotion of tumor growth, angiogenesis, and invasion, have been attributed to the different cell types populating the tumor stroma, i.e., endothelial cells, cancer-associated fibroblasts, pericytes, and infiltrating inflammatory cells. Fibroblasts have long been recognized inside carcinomas and are increasingly implicated as functional participants. The stroma is prominent in cervical carcinoma, and distinguishable from nonmalignant tissue, suggestive of altered (tumor-promoting) functions. We postulated that pharmacological targeting of putative stromal support functions, in particular those of cancer-associated fibroblasts, could have therapeutic utility, and sought to assess the possibility in a pre-clinical setting.<h4>Methods and findings</h4>We used a genetically engineered mouse model of cervical carcinogenesis to investigate platelet-derived growth factor (PDGF) receptor signaling in cancer-associated fibroblasts and pericytes. Pharmacological blockade of PDGF receptor signaling with the clinically approved kinase inhibitor imatinib slowed progression of premalignant cervical lesions in this model, and impaired the growth of preexisting invasive carcinomas. Inhibition of stromal PDGF receptors reduced proliferation and angiogenesis in cervical lesions through a mechanism involving suppression of expression of the angiogenic factor fibroblast growth factor 2 (FGF-2) and the epithelial cell growth factor FGF-7 by cancer-associated fibroblasts. Treatment with neutralizing antibodies to the PDGF receptors recapitulated these effects. A ligand trap for the FGFs impaired the angiogenic phenotype similarly to imatinib. Thus PDGF ligands expressed by cancerous epithelia evidently stimulate PDGFR-expressing stroma to up-regulate FGFs, promoting angiogenesis and epithelial proliferation, elements of a multicellular signaling network that elicits functional capabilities in the tumor microenvironment.<h4>Conclusions</h4>This study illustrates the therapeutic benefits in a mouse model of human cervical cancer of mechanism-based targeting of the stroma, in particular cancer-associated fibroblasts. Drugs aimed at stromal fibroblast signals and effector functions may prove complementary to conventional treatments targeting the overt cancer cells for a range of solid tumors, possibly including cervical carcinoma, the second most common lethal malignancy in women worldwide, for which management remains poor.
first_indexed 2024-12-14T06:16:33Z
format Article
id doaj.art-9c65748b24e944daa7f342557e9cccfa
institution Directory Open Access Journal
issn 1549-1277
1549-1676
language English
last_indexed 2024-12-14T06:16:33Z
publishDate 2008-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Medicine
spelling doaj.art-9c65748b24e944daa7f342557e9cccfa2022-12-21T23:14:00ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762008-01-0151e1910.1371/journal.pmed.0050019Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.Kristian PietrasJessica PahlerGabriele BergersDouglas Hanahan<h4>Background</h4>Important support functions, including promotion of tumor growth, angiogenesis, and invasion, have been attributed to the different cell types populating the tumor stroma, i.e., endothelial cells, cancer-associated fibroblasts, pericytes, and infiltrating inflammatory cells. Fibroblasts have long been recognized inside carcinomas and are increasingly implicated as functional participants. The stroma is prominent in cervical carcinoma, and distinguishable from nonmalignant tissue, suggestive of altered (tumor-promoting) functions. We postulated that pharmacological targeting of putative stromal support functions, in particular those of cancer-associated fibroblasts, could have therapeutic utility, and sought to assess the possibility in a pre-clinical setting.<h4>Methods and findings</h4>We used a genetically engineered mouse model of cervical carcinogenesis to investigate platelet-derived growth factor (PDGF) receptor signaling in cancer-associated fibroblasts and pericytes. Pharmacological blockade of PDGF receptor signaling with the clinically approved kinase inhibitor imatinib slowed progression of premalignant cervical lesions in this model, and impaired the growth of preexisting invasive carcinomas. Inhibition of stromal PDGF receptors reduced proliferation and angiogenesis in cervical lesions through a mechanism involving suppression of expression of the angiogenic factor fibroblast growth factor 2 (FGF-2) and the epithelial cell growth factor FGF-7 by cancer-associated fibroblasts. Treatment with neutralizing antibodies to the PDGF receptors recapitulated these effects. A ligand trap for the FGFs impaired the angiogenic phenotype similarly to imatinib. Thus PDGF ligands expressed by cancerous epithelia evidently stimulate PDGFR-expressing stroma to up-regulate FGFs, promoting angiogenesis and epithelial proliferation, elements of a multicellular signaling network that elicits functional capabilities in the tumor microenvironment.<h4>Conclusions</h4>This study illustrates the therapeutic benefits in a mouse model of human cervical cancer of mechanism-based targeting of the stroma, in particular cancer-associated fibroblasts. Drugs aimed at stromal fibroblast signals and effector functions may prove complementary to conventional treatments targeting the overt cancer cells for a range of solid tumors, possibly including cervical carcinoma, the second most common lethal malignancy in women worldwide, for which management remains poor.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18232728/?tool=EBI
spellingShingle Kristian Pietras
Jessica Pahler
Gabriele Bergers
Douglas Hanahan
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
PLoS Medicine
title Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
title_full Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
title_fullStr Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
title_full_unstemmed Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
title_short Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
title_sort functions of paracrine pdgf signaling in the proangiogenic tumor stroma revealed by pharmacological targeting
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18232728/?tool=EBI
work_keys_str_mv AT kristianpietras functionsofparacrinepdgfsignalingintheproangiogenictumorstromarevealedbypharmacologicaltargeting
AT jessicapahler functionsofparacrinepdgfsignalingintheproangiogenictumorstromarevealedbypharmacologicaltargeting
AT gabrielebergers functionsofparacrinepdgfsignalingintheproangiogenictumorstromarevealedbypharmacologicaltargeting
AT douglashanahan functionsofparacrinepdgfsignalingintheproangiogenictumorstromarevealedbypharmacologicaltargeting